Abstract:Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoid neoplasm. This study aims to investigate whether the immunologically relevant lymphocyte-to-monocyte ratio (LMR) can predict outcome of newly diagnosed DLBCL in the rituximab era. We analyzed retrospective data from 53 newly diagnosed DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Receiver operating characteristic (ROC) curve analysis was used to generate a cutoff value for LMR with an area under the curve =0.728 (P=0.021). The sensitivity and specificity for LMR were 69% and 73%, respectively. We found that a low LMR (< 2.2) correlates with higher biological marker-adjusted International Prognostic Index (B-IPI) score (P=0.011). Patients with a low LMR (39.6% of all cases) were found to have significantly prolonged overall survival (OS) and progression-free survival (PFS). This study suggests that the LMR, a surrogate biomarker of host immune, can be used as a marker to assess prognosis of DLBCL after standard first-line chemotherapy.

Peripheral Blood Lymphocyte-To-Monocyte Ratio Is A Useful Prognostic Factor In Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Chemoimmunotherapy